Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867642 | 0.82 | KMT2A (0.41) | ALDH1A1KMT2AMAPTHTTPOLB | |
| SCHEMBL10102711 | 0.82 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPTHTTPOLB | |
| SCHEMBL10102722 | 0.81 | MAPT (0.36) | ALDH1A1KMT2AMAPTHTTPOLB | |
| SCHEMBL16882295 | 0.80 | KMT2A (0.37) | ALDH1A1KMT2AMAPTHTTPOLB | |
| SCHEMBL10102780 | 0.79 | ALDH1A1 (0.39) | ALDH1A1KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL10102723 | 0.78 | ATM (0.33) | ALDH1A1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL11982518 | 0.78 | KMT2A (0.50) | ALDH1A1KMT2AMAPTHTTPOLB | |
| SCHEMBL10102747 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL10102719 | 0.77 | ATM (0.33) | ALDH1A1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL10108151 | 0.77 | ATM (0.33) | ALDH1A1KMT2AMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-04 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9101632-B2 | Kinase inhibitors, prodrug forms thereof and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-08-11 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-08-09 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| WO-2011028135-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010104406-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | ALDH1A1 3257/4885KMT2A 1235/4885MAPT 3315/4885 |
| US-20160031877-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, ERBB3 | ALDH1A1 2362/4885KMT2A 810/4885MAPT 4568/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | ALDH1A1 3205/4885KMT2A 1810/4885MAPT 3259/4885 |
| US-20120202832-A1 | KINASE INHIBITORS, PRODRUG FORMS THEREOF AND THEIR USE IN THERAPY | ERBB2, MAP3K3, MAP3K19 | ALDH1A1 2355/4885KMT2A 744/4885MAPT 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.